BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. Chest 2021;159:517-23. [PMID: 32712225 DOI: 10.1016/j.chest.2020.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Aksamit TR, Marras TK. Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria: A Call to Arms. Chest 2021;160:e90. [PMID: 34246401 DOI: 10.1016/j.chest.2021.02.059] [Reference Citation Analysis]
2 Kwak N, Whang J, Yim JJ. Response. Chest 2021;160:e91. [PMID: 34246402 DOI: 10.1016/j.chest.2021.02.058] [Reference Citation Analysis]
3 Griffith DE, Winthrop KL. You Gotta Make Me See, What Does It Mean to Have an MIC? Chest 2021;159:462-4. [PMID: 33563427 DOI: 10.1016/j.chest.2020.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim BG, Kim H, Kwon OJ, Huh HJ, Lee NY, Baek SY, Sohn I, Jhun BW. Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease. J Clin Med 2020;9:E2968. [PMID: 32937940 DOI: 10.3390/jcm9092968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Park Y, Park YE, Jhun BW, Park J, Kwak N, Jo KW, Yim JJ, Shim TS, Kang YA. Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of Mycobacterium abscessus Pulmonary Disease. Open Forum Infect Dis 2021;8:ofab215. [PMID: 34189168 DOI: 10.1093/ofid/ofab215] [Reference Citation Analysis]
6 Kamada K, Mitarai S. Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem? Antibiotics (Basel) 2021;11:19. [PMID: 35052896 DOI: 10.3390/antibiotics11010019] [Reference Citation Analysis]
7 Schulthess B, Akdoğan Kittana FN, Hömke R, Sander P. In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus. Antimicrob Agents Chemother 2022;:e0234621. [PMID: 35420492 DOI: 10.1128/aac.02346-21] [Reference Citation Analysis]
8 Lee JM, Park J, Choi S, Jhun BW, Kim SY, Jo KW, Hong JJ, Kim LH, Shin SJ. A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex. Front Microbiol 2020;11:626216. [PMID: 33519787 DOI: 10.3389/fmicb.2020.626216] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Alffenaar JW, Märtson AG, Heysell SK, Cho JG, Patanwala A, Burch G, Kim HY, Sturkenboom MGG, Byrne A, Marriott D, Sandaradura I, Tiberi S, Sintchencko V, Srivastava S, Peloquin CA. Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. Clin Pharmacokinet 2021;60:711-25. [PMID: 33751415 DOI: 10.1007/s40262-021-01000-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fujiwara K, Uesugi F, Furuuchi K, Tanaka Y, Yoshiyama T, Saotome M, Ohta K, Mitarai S, Morimoto K. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease. Microbiol Spectr 2021;9:e0192821. [PMID: 34878300 DOI: 10.1128/Spectrum.01928-21] [Reference Citation Analysis]
11 Asami T, Aono A, Chikamatsu K, Igarashi Y, Morishige Y, Murase Y, Yamada H, Takaki A, Mitarai S. Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium abscessus subsp. abscessus in vitro. JAC Antimicrob Resist 2021;3:dlab004. [PMID: 34223082 DOI: 10.1093/jacamr/dlab004] [Reference Citation Analysis]